Search Results

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Complimentary Reception dinner MENU Four Mushroom Soup Tomato, Panela Cheese, and Spinach tower with Oregano Vinaigrette Cane Sugar and Arbol Chile Lacquered Duck Monte Cristo Chocolate Cake Coffee or Tea Vegetarian option* -Mushroom-stuffed chiles on refried bean sauce- instead of the duck < Previous Session Next Session >

Home → Flash News → This new study reveals how the conformation of parathyroid hormone (PTH) and the C-terminal helix α5 of Gα regulate the selective coupling of PTH1R to Gs or Gq. Through Cryo-EM and single-cell experiments, the authors show differences in binding affinity, duration, and strength. Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox ➡️ https://www.ecosystem.drgpcr.com/structural-and-molecular-insights-into-gpcr-function/allosteric-mechanism-in-the-distinctive-coupling-of-gq-and-gs-to-the-parathyroid-hormone-type-1-receptor #gpcr #drgpcr Published on April 28, 2025 Category GPCR Weekly News This new study reveals how the conformation of parathyroid hormone (PTH) and the C-terminal helix α5 of Gα regulate the selective coupling of PTH1R to Gs or Gq. Through Cryo-EM and single-cell experiments, the authors show differences in binding affinity, duration, and strength. Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox ➡️ https://www.ecosystem.drgpcr.com/structural-and-molecular-insights-into-gpcr-function/allosteric-mechanism-in-the-distinctive-coupling-of-gq-and-gs-to-the-parathyroid-hormone-type-1-receptor #gpcr #drgpcr Previous Next Recent Articles

<< Back to podcast list Strategic Partner(s) Irfan Dhanidina, Dr. Kathleen Caron and Dr. Lauren Slosky About Irfan Dhanidina "My interest in oncology research led me to pursue a BSc in Biology & Economics from Carleton University, and an MSc in Biotechnology at McGill. However, after insightful experiences in academic, hospital, and industry labs, I decided to pursue a role in business development. In my role at Orion Biotechnology, I work at the intersection of science and business, which includes target selection, preclinical strategy and business development. With respect to GPCRs, I'm particularly interested in peptide/small protein receptors and the mechanisms that facilitate their role in various indications. To that end, I'm grateful to be working alongside the very talented team at Orion who translate important GPCR research into novel therapies for patients. " Irfan Dhanidina on the web LinkedIn The Org DIBIZ Dr. GPCR About Dr. Kathleen Caron " "Kathleen M. Caron, Ph.D. is the Frederik L. Eldridge Distinguished Professor and Chair of the Department of Cell Biology & Physiology at The University of North Carolina at Chapel Hill—a large, interdisciplinary basic science department consistently ranked in the Top 5 in the Nation in NIH funding. Dr. Caron received a BS in Biology and BA in Philosophy at Emory University and a PhD at Duke University while training with Dr. Keith Parker to elucidate the role of steroidogenesis in regulating sexual determination and adrenal and gonadal development using genetic mouse models. She pursued postdoctoral training with Nobel Laureate Dr. Oliver Smithies at UNC-CH, where she was the first to discover the essential role of adrenomedullin peptide for embryonic survival. With a special emphasis on G protein coupled receptors and receptor activity modifying proteins in vascular biology, the Caron laboratory has gained valuable insights into the genetic basis and pathophysiology of lymphatic vascular disease, preeclampsia and sex-dependent cardiovascular disease. Dr. Caron has received numerous awards including a Burroughs Wellcome Fund Career Award in the Biomedical Sciences, an Established Investigator Award and an Innovator Award from the American Heart Association, a Jefferson Pilot Award in Biomedical Sciences and a UNC-CH Mentoring Award. She currently serves as Associate Editor of Physiological Reviews; the #1 ranked journal in Physiology (IF 46.5). Dr. Caron is also past Associate Editor at JCI and served as the inaugural Associate Editor at ACS-Pharmacology and Translational Science. Dr. Caron currently holds multiple scientific advisory roles in academia, industry and the National Institutes of Health." " Dr. Kathleen Caron on the web UNC-Chapel Hill Department of Cell Biology and Physiology UNC Lineberger Comprehensive Cancer Center Twitter Google Scholar ORCID ResearchGate Dr. GPCR About Dr. Lauren Slosky "Lauren Slosky is an Assistant Professor in the Department of Pharmacology and a member of the Medical Discovery Team on Addiction, a multidisciplinary initiative within the University of Minnesota’s Medical School to advance research and treatment in the field of drug addiction. Dr. Slosky’s research is focused on understanding how neuropeptide G protein-coupled receptors (GPCRs) regulate motivated behavior and how these receptors can be targeted for therapeutic benefit. Dr. Slosky was awarded a B.S. with honors in Molecular and Cellular Biology and Psychology from The University of Arizona in 2011. She received a Ph.D. in Medical Pharmacology from The University of Arizona in 2015 and completed a postdoctoral fellowship in the laboratory of Dr. Marc G. Caron at Duke University. Dr. Slosky opened her laboratory at the University of Minnesota Medical School in 2021. While a postdoctoral fellow, Dr. Slosky characterized a new class of β-arrestin biased allosteric modulators (BAMs) for the neurotensin receptor 1. These ligands stimulate receptor β-arrestin recruitment without activating canonical G protein signaling. Critically, these ligands reduce addiction-associated behaviors in animal models without the side effects characteristic of balanced receptor activation. Because BAMs engage less well-conserved allosteric sites and exert pathway-specific effects on receptor signaling, they are exciting tools for linking distinct signaling pathways with their physiological effects and may serve as the basis for more selective therapeutics. This work was made possible by the optimization of longitudinal intravenous self-administration paradigms for genetically modified mice. Integrating GPCR biology, behavioral pharmacology, and systems neuroscience approaches, the Slosky Lab is now working to understand how the principles of receptor allosterism and functional selectivity can be leveraged in the development of safe and effective treatments for stimulant and opioid use disorders. Dr. Slosky’s work has been recognized through several travel and research awards, including the William James Psychology Award, the Hank Yamamura Endowed Fellowship in Pharmacology, an NIH F32 Postdoctoral Fellowship, and an NIH K99/R00 Pathway to Independence Award. In addition to research, Dr. Slosky is passionate about training the next generation of scientists and increasing diversity, equity, and inclusion in science. An advocate for trainees at all levels, she served as Service Chairperson and Interim President of the Duke University Postdoctoral Association. She is currently a faculty trainer for the University of Minnesota's MS and Ph.D. programs in Pharmacology, Graduate Program in Neuroscience, and Life Sciences Summer Undergraduate Research Program and is working to build relationships with key stakeholders through institutional and community service." Dr. Lauren Slosky on the web University of Minnesota Department Page Twitter LinkedIn Google Scholar PubMed Research Gate Dr. GPCR Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Aylin Hanyaloglu About Dr. Aylin Hanyaloglu Dr. Aylin Hanyaloglu has been a Principal Investigator at Imperial College London since 2007. She received her BSc in Human Biology from King’s College London in 1997, and while her Ph.D. commenced at the MRC Human Reproductive Sciences Centre, Edinburgh, a move to Perth, Australia resulted in her Ph.D. in Molecular Endocrinology being awarded in 2002 with Distinction from the University of Western Australia. Dr. Hanyaloglu undertook her postdoctoral training at the University of California, San Francisco with Professor Mark von Zastrow where she identified novel core cellular machinery critical for G protein-coupled receptor trafficking and signaling. Her research focuses on understanding the fundamental cell biological mechanisms regulating GPCR activity, including spatial control of GPCR signaling and receptor crosstalk, and applying these mechanisms for distinct GPCRs in diverse physiological and pathophysiological systems, with particular focus on women's health, pregnancy, and nutrient sensing in the gut. Her work is currently funded by Biotechnology and Biological Sciences Research Council (BBSRC), Diabetes UK, Wellcome Trust, and the Medical Research Council. Dr. Aylin Hanyaloglu on the web LinkedIn Researchgate Twitter Imperial College London Elsevier Loop Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Jean-Philippe Pin About Dr. Jean-Philippe Pin Jean-Philippe Pin participated in the discovery of metabotropic glutamate receptors. Since then, he has been studying the allosteric modulation and activation mechanism of this family of G protein-coupled receptors using innovative approaches, including biosensors, cryo-EM, photoswitchable ligands, and nanobodies as pharmacological tools and potential therapeutic agents. His studies led to new concepts in the GPCR field, such as the activation of cell surface receptors by intracellular proteins; the regulation of GPCRs by both negative and positive allosteric modulators, and the asymmetric functioning of GPCR dimers. Dr. Jean-Philippe Pin on the web LinkedIn ResearchGate CNRS Fondation Bettencourt Schueller FRC Neurodon Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Elva Zhao About this episode Elva is currently a research fellow at the Monash Institute of Pharmaceutical Sciences. Elva moved to Canada where she obtained her Ph.D. at the University of Western Ontario, working on the regulation of G proteins signaling by accessory proteins, such as RGS proteins and GPSM proteins. After her Ph.D., she moved to Australia and continues working on GPCRs. Her current research focuses on class B GPCRs and understanding how GPCR signaling and function is mediated by various ligands, binding partners, and intracellular machinery. In her spare time, Elva likes to run in the mountains, play with Tilly (a 9-year old retired greyhound), collecting mini shoes, and hang out with friends. Join me to learn more about Elva, class B GPCRs, and Tilly. Dr. Elva Zhao on the web LinkedIn Monash University Pubmed Twitter Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Françoise Bachelerie About Dr. Françoise Bachelerie " FB leads a team at Paris-Saclay University with expertise in immunology and virology related to Host/Virus interactions and GPCR function. The team’s projects are devoted to the activation/function of CXCR4-ACKR3 (CXCR7) receptors of the CXCL12 chemokine, key effectors of the immune system, including their role in immunological disorders (e.g. WHIM syndrome) and in the innate control of the life cycle of papillomavirus, which are commensal inhabiting the healthy human epithelium (virome) while presenting an oncogenic potential that remains a major health concern. FB is recognized for her expertise and pioneering works in the field of biological and pathological functions of chemokines and their receptors, for which she made important breakthroughs regarding the CXCL12/CXCR4/ACKR3 trio. In particular, FB contributed to the discovery that CXCL12 is the ligand for the CXCR4 receptor and can therefore prevent infection by the Human Immunodeficiency Virus (HIV). FB’ team has identified the orphan CXCR7/ACKR3 receptor as being the 2nd receptor for CXCL12, which behaves as a modulator of CXCL12/CXCR4 functions. FB is a member of various international committees in the field, including the one that reviewed the standard nomenclature for chemokine receptors that are categorized into a large subgroup of G protein–coupled (GPCR) leukocyte chemotactic receptors (including CXCR4), and a smaller subgroup of atypical chemokine receptors (including the CXCR7/ACKR3). " Dr. Françoise Bachelerie on the web INSERM ResearchGate SciSpace Loop LinkedIn Dr. GPCR Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Home → Flash News → 🚨 Exciting Opportunity for Professionals in Drug Development! 🚨 Register today for a one-of-a-kind online course at Dr. GPCR University: "Development of GPCR Ligands as Therapeutic Drugs." 🗓 Dates: March 20 - April 10, 2025 ⏰ Time: Thursdays, 10:00 AM - 11:30 AM (EST) This advanced course is essential for anyone working in drug development and focuses on: The essentials of new drug development Key pharmacokinetic elements (absorption, distribution, clearance) Hepatic metabolism and the Cytochrome P450 system Drug safety and toxicology (including drug-drug interactions) And much more! Gain deep insights into GPCR drug candidates and learn the critical assays and techniques required to bring therapeutic molecules to life. 🚨 Only 25 spots available — register now! 💡 This is a great opportunity for both academia and industry professionals. Sessions will be live, and you’ll also have 1:1 discussion time with the instructor. Full PDFs of the slides will be available! 🔗 https://buff.ly/lVEcRUc #GPCR #DrugDevelopment #Pharmacokinetics #TherapeuticDrugs #OnlineCourse #DrGPCRUniversity #PharmaceuticalIndustry Published on March 12, 2025 Category Dr. GPCR Courses 🚨 Exciting Opportunity for Professionals in Drug Development! 🚨 Register today for a one-of-a-kind online course at Dr. GPCR University: "Development of GPCR Ligands as Therapeutic Drugs." 🗓 Dates: March 20 - April 10, 2025 ⏰ Time: Thursdays, 10:00 AM - 11:30 AM (EST) This advanced course is essential for anyone working in drug development and focuses on: The essentials of new drug development Key pharmacokinetic elements (absorption, distribution, clearance) Hepatic metabolism and the Cytochrome P450 system Drug safety and toxicology (including drug-drug interactions) And much more! Gain deep insights into GPCR drug candidates and learn the critical assays and techniques required to bring therapeutic molecules to life. 🚨 Only 25 spots available — register now! 💡 This is a great opportunity for both academia and industry professionals. Sessions will be live, and you’ll also have 1:1 discussion time with the instructor. Full PDFs of the slides will be available! 🔗 https://buff.ly/lVEcRUc #GPCR #DrugDevelopment #Pharmacokinetics #TherapeuticDrugs #OnlineCourse #DrGPCRUniversity #PharmaceuticalIndustry Previous Next Recent Articles

Home → Flash News → 🚀 Science and finance aren't opposites—they’re partners. In this Ep.165 of the Dr.GPCR Podcast, Joe St. Germain & Chuck DeWeese reveal what it really takes to build sustainable startups and nonprofits behind the scenes. Grant accounting, character-first hiring, mission-driven growth—it’s all here! 🎧 Listen now: Ep 165 with Chuck DeWeese & Joe St. Germain #gpcr #DrGPCR #ScienceStartup Published on April 29, 2025 Category Dr. GPCR Podcast 🚀 Science and finance aren't opposites—they’re partners. In this Ep.165 of the Dr.GPCR Podcast, Joe St. Germain & Chuck DeWeese reveal what it really takes to build sustainable startups and nonprofits behind the scenes. Grant accounting, character-first hiring, mission-driven growth—it’s all here! 🎧 Listen now: Ep 165 with Chuck DeWeese & Joe St. Germain #gpcr #DrGPCR #ScienceStartup Previous Next Recent Articles

Home → Flash News → What if you could map GPCR-RAMP interactions across the entire superfamily in a single experiment? That’s precisely what Dr. Kotliar from the Sakmar lab made possible! In Ep.167 of the Dr. GPCR Podcast, we chat with Drs. Tom Sakmar and Ilana Kotliar about how their lab developed: A multiplexed Luminex assay to screen hundreds of interactions at once A 220-clone DUET-tagged GPCR library, available on Addgene An online interface to search GPCR-RAMP data and antibody validations This is open-access science at its best, built for the GPCR research community. ✳️ Listen to the episode: Ep 167 with Drs. Tom Sakmar & Ilana Kotliar #GPCRresearch #DrGPCRecosystem #GPCRdrugdiscovery #GPCRtrainingprogram #GPCRpodcast Published on May 27, 2025 Category Dr. GPCR Podcast What if you could map GPCR-RAMP interactions across the entire superfamily in a single experiment? That’s precisely what Dr. Kotliar from the Sakmar lab made possible! In Ep.167 of the Dr. GPCR Podcast, we chat with Drs. Tom Sakmar and Ilana Kotliar about how their lab developed: A multiplexed Luminex assay to screen hundreds of interactions at once A 220-clone DUET-tagged GPCR library, available on Addgene An online interface to search GPCR-RAMP data and antibody validations This is open-access science at its best, built for the GPCR research community. ✳️ Listen to the episode: Ep 167 with Drs. Tom Sakmar & Ilana Kotliar #GPCRresearch #DrGPCRecosystem #GPCRdrugdiscovery #GPCRtrainingprogram #GPCRpodcast Previous Next Recent Articles

Home → Flash News → Unlock your pharmacology potential with Terry’s Corner. No fluff. Just clear, on-demand insight from Dr. Terry Kenakin—built for scientists at every level. 🟢 Building core expertise? Learn dose-response, agonism, binding, bias, kinetics, and the models that build real confidence. 🟢 Driving drug discovery? Apply pharmacology to selectivity, ADME, early safety, and smarter decision-making. 🟢 Already a drug hunter? Sharpen your edge with allosteric modulation, residence time, molecular dynamics, and translational PK/PD. Learn on-demand. Apply immediately. Early access begins July 1 → https://www.terrykenakin.com #pharmacology #GPCRscience #drugdiscovery #TerrysCorner #biotechtraining Published on June 28, 2025 Category Terry's Corner Unlock your pharmacology potential with Terry’s Corner. No fluff. Just clear, on-demand insight from Dr. Terry Kenakin—built for scientists at every level. 🟢 Building core expertise? Learn dose-response, agonism, binding, bias, kinetics, and the models that build real confidence. 🟢 Driving drug discovery? Apply pharmacology to selectivity, ADME, early safety, and smarter decision-making. 🟢 Already a drug hunter? Sharpen your edge with allosteric modulation, residence time, molecular dynamics, and translational PK/PD. Learn on-demand. Apply immediately. Early access begins July 1 → https://www.terrykenakin.com #pharmacology #GPCRscience #drugdiscovery #TerrysCorner #biotechtraining Previous Next Recent Articles

<< Back to podcast list Strategic Partner(s) Dr. Josephine (Pina) Cardarelli About Dr. Josephine (Pina) Cardarelli Dr. Pina Cardarelli, CSO for GPCR Therapeutics Inc., based in South Korea, has recently been named President of GPCR Therapeutics, USA, a newly incorporated Biotechnology company in the Bay Area. The company’s mission is to discover and develop highly effective cancer therapeutics by targeting heteromers of G protein-coupled receptors (GPCR). Burixafor, their most advanced clinical candidate, will be in Phase II clinical trial next year. Additionally, they have a library of target GPCR heteromers for Oncology. Dr. Cardarelli heads the team of talented researchers that will be expanding at the US site. Dr. Cardarelli is a drug development leader with extensive experience driving drug discovery teams in bringing biologics to clinical proof of concepts. She has expertise in cell biology, pharmacology, translational medicine, oncology, immuno-oncology, immunology, and clinical development. Previously, she held the position of Vice President of Cell Biology & Pharmacology, at Bristol-Myers Squibb . She was an integral contributor to two therapeutics that are FDA approved, Yervoy and Opdivo. She was a participant in numerous due diligence (anti-CXCL8 mAb) and has managed external collaborations and alliances. Prior to this, she held the position of Vice President, at Medarex, Inc . While at BMS and Medarex, she led programs from target ID to clinical development that included, CXCL10 (Eldelumab), CXCR4 (Ulocuplumab), CD30, CD19, Fucosyl GM-1, & mesothelin-ADC, Glypican-3-ADC, CD70-ADC. She oversaw early discovery programs IL-23 p19 and IL23 p19/IL-17 bispecifics. At Medarex, she initiated and identified the lead mAb for the type I interferon-alpha receptor project, licensed to AstraZeneca (Saphnelo™ Anifrolumab) that has just received FDA approval for systemic lupus erythematosus. She has extensive experience working with Biologics, and Antibody Drug Conjugates as well as experience in IND fillings, IB updates, and responding to FDA inquiries. She is an inventor on 39 issued U.S. patents including anti-PD-1 patents, 22 EP patents, and greater than 100 global patents centered around therapeutic development. She has also authored forty-six peer-reviewed publications. Dr. Cardarelli received her Ph.D. in Physiology from Albany Medical College. Dr. Josephine (Pina) Cardarelli on the web LinkedIn Company Website Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Home → Flash News → 🔬 Enhance Your GPCR Expertise with Dr.GPCR University! Looking to sharpen your skills in GPCR pharmacology, drug discovery, data analysis, or project management? Dr.GPCR University offers industry-focused courses designed to help you stay ahead in the field. ✅ Comprehensive course library covering cutting-edge GPCR science ✅ Practical insights for real-world drug discovery challenges ✅ Flexible, on-demand learning to fit your schedule 🚀 Elevate your expertise today: Start learning now #GPCR #Pharmacology #DrugDiscovery #Biotech #DrGPCR Published on March 11, 2025 Category GPCR Weekly News 🔬 Enhance Your GPCR Expertise with Dr.GPCR University! Looking to sharpen your skills in GPCR pharmacology, drug discovery, data analysis, or project management ? Dr.GPCR University offers industry-focused courses designed to help you stay ahead in the field. ✅ Comprehensive course library covering cutting-edge GPCR science✅ Practical insights for real-world drug discovery challenges✅ Flexible, on-demand learning to fit your schedule 🚀 Elevate your expertise today: Start learning now #GPCR #Pharmacology #DrugDiscovery #Biotech #DrGPCR Previous Next Recent Articles

<< Back to podcast list Strategic Partner(s) Dr. Andrew Tobin About Dr. Andrew Tobin Andrew Tobin studied Biochemistry at Queen Mary College, the University of London obtaining first-class honors before studying for a Dr. Phil at the University of Oxford. Following a post-doctoral period at Bristol Myers Squibb in Princeton USA, Andrew returned to the UK to establish his own laboratory at the University of Leicester. Funded through three consecutive Wellcome Trust Senior Research Fellowships Andrew established a reputation in the field of receptor signaling. Now at the University of Glasgow, his primary research interests are focused on the rational design of novel drugs to treat the three global health challenges of dementia, asthma, and malaria. In this Andrew runs a research laboratory of around 15 staff supported by basic research grants investigating aspects of disease biology and the action of drugs in the context of disease. The vehicle by which Andrew is translating fundamental findings to commercial products is Keltic Pharma Therapeutics Ltd , a biotechnology company co-founded by Andrew with series A funding from the European Union. Andrew is also the Director of the Advanced Research Centre (ARC) a collaborative initiative at the University of Glasgow underpinned by a £118M new build that will house over 550 researchers designed to drive interdisciplinary research. Dr. Andrew Tobin on the web University of Glasgow ResearchGate Google Scholar Twitter Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Thomas P. Sakmar About Dr. Thomas P. Sakmar Tom Sakmar is a physician-scientist and professor at Rockefeller University in New York. While a chemistry undergraduate student at the University of Chicago, he attended a NATO Advanced Study Institute in Les Houches, France in 1979 where he was exposed for the first time to the nascent field of membrane biophysics and intercellular communication. Instructors at the course included Marc Chabre , Harden McConnell , Richard Henderson , Martin Rodbell , Jean-Pierre Changeux , and Martin Karplus . After medical school and clinical training at Massachusetts General Hospital, Tom joined the laboratory of H. Gobind Khorana at the Department of Chemistry at M.I.T. for postdoctoral training, where he learned gene synthesis, cDNA cloning, site-directed mutagenesis, and heterologous expression in mammalian cells. Khorana’s lab made early key contributions and developed strategies to express, reconstitute and assay engineered GPCRs using the visual pigment rhodopsin as a model system. Tom initially focused on structure-activity relationships underlying spectral tuning and identified a glutamic acid residue in rhodopsin that serves as the retinylidene Schiff base counterion. He also went on to discover a “counterion switch” in visual pigments and to develop strategies to assay receptor-G-protein interactions and activation kinetics. After moving to Rockefeller University with a Howard Hughes Medical Institute appointment, Tom advanced a series of novel biochemical and biophysical assay platforms, including FTIR and Raman microprobe spectroscopy to study micro-quantities of expressed visual pigment mutants. This work involved active long-term collaborators, including Richard Mathies and Fritz Siebert , and contributed substantially to elucidating the physical chemistry of spectral tuning, and to a better understanding of the molecular mechanism of activation of GPCRs. Many of the conceptual advances that stemmed from this work, such as the concept of “functional micro-domains” and the “helix movement model of receptor activation” were confirmed later when crystal structures became available. Tom’s lab also pioneered the early use of computational homology modeling, molecular dynamics simulations and coarse-grain sampling approaches for membrane proteins in collaborations with Thomas Huber , Xavier Periole , and Siewert-Jan Marrink . Tom’s lab also developed an amber codon suppression method to genetically encode unnatural amino acids into membrane proteins expressed in mammalian cell culture. The genetic code expansion strategy for unnatural amino acid mutagenesis is a key enabling technology for the field and is being used by many laboratories. Early applications included “targeted photo-crosslinking,” and more recently, the parallel development of bioorthogonal labeling strategies to couple fluorophores to expressed receptors and other membrane proteins has allowed the creation of novel sensor constructs and single-molecule detection strategies. Recently, Tom’s lab discovered, along with Yu Chen and Ping Chi , that a mutant of CYSLTR2 is a driver oncogene in uveal melanoma, the most common eye cancer in adults. The CysLTR2 oncoprotein displays biased constitutive activity – it activates Gq/11 but does not undergo β-arrestin-mediated down-regulation. Dr. Thomas P. Sakmar on the web LinkedIn ResearchGate Pubmed ORCHID Google Scholar Rockefeller University Wikipedia Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Home → Flash News → An opportunity you won’t want to miss! ⚠️ The next 4-week course with Dr. Terry Kenakin, “Development of GPCR Ligands as Therapeutic Drugs” is coming up 🧐 Be the first to register, save your spot, and spread the word. This event will only happen once this year! ✳️Go to https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs for more information! #gpcr #drgpcr Published on February 19, 2025 Category Dr. GPCR Courses An opportunity you won’t want to miss! ⚠️ The next 4-week course with Dr. Terry Kenakin, “Development of GPCR Ligands as Therapeutic Drugs” is coming up 🧐 Be the first to register, save your spot, and spread the word. This event will only happen once this year! ✳️Go to https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs for more information! #gpcr #drgpcr Previous Next Recent Articles

<< Back to podcast list Strategic Partner(s) Dr. Mark Connor About Dr. Mark Connor Undergraduate BSc with Honours in Pharmacology from University of Sydney (1987, snake neurotoxins), Ph.D. from Department of Pharmacology, University of Washington (1992, mentor Charley Chavkin , sigma receptors). Postdoc with Graeme Henderson (Bristol, opioids and Ca signaling) and Mac Christie (Sydney, opioids in neurons, novel spider toxins). Grant-funded independent research positions from 2001 at University of Sydney (opioids and sensory neurons), Vollum Institute Portland (visiting scientist with Ed McCleskey, sensory neuron properties); Pain Management Research Institute (more opioids, cannabinoids and T-type Ca channels) and Brain and Mind Research Institute (Sydney). 2009, appointed Professor of Pharmacology at Macquarie University. Focus on study of drugs and toxins on GPCR (opioid, cannabinoid receptor) and ion channel (K, Ca, TRP channel) function; mostly electrophysiology and fluorescence-based reporters, but can grind and bind. Currently pursuing molecular pharmacology of phytocannabinoids and novel synthetic cannabinoids, with a focus on efficacy and novel targets. Interested in orthosteric and allosteric interactions, and still looking for some bias ... anywhere ... these days human only. Dr. Mark Connor on the web Researchers Twitter Google Scholar Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Roger Sunahara About Dr. Roger Sunahara Professor Sunahara received his graduate training with Dr. Philip Seeman in the Department of Pharmacology at the University of Toronto. He later joined the laboratory of eminent biochemical pharmacologist, Dr. Alfred G. Gilman, at the University of Texas Southwestern Medical School as a post-doctoral fellow. His training has provided a strong foundation and appreciation for the applications of pharmacology, biochemistry and structural biology to delineate mechanisms of action. Professor Sunahara started his independent research career in the Department of Pharmacology at the University of Michigan Medical School, where he climbed the academic ladder. In 2015 Professor Sunahara moved his laboratory to the Department of Pharmacology at the University of California in San Diego. His main area of research focuses on the structural and pharmacological bases for hormone-mediated activation of G proteins by G protein-coupled receptors (GPCRs). The Sunahara lab utilizes biochemical, biophysical and pharmacological methodologies to study GPCR-G protein interactions. These approaches were invaluable to resolve the crystal structure of the beta2-adrenergic receptor (beta2AR)-G protein complex, team effort with long time collaborator Brian Kobilka . The structure was first snapshot of the agonist- and G protein-bound GPCR, providing valuable models for agonist-mediated activation of G proteins. We continue to utilize these data to better understand the basis for receptor-G protein specificity and agonist efficacy. Our mission is to understand the mechanism and structural bases for ligand binding and efficacy to help optimize the design and engineering of more efficacious therapeutics. This is an important perspective in the pursuit of receptor subtype-specific ligands, a major aspect to achieve safer, on-target therapeutics. One example of our recent work surrounds a structure-based effort to develop ligands that specifically target the beta2AR above all other adrenergic receptor isoforms. Our goal is to develop safer beta2AR-selective ligands for the treatment of asthma and acute rescue therapy for anaphylaxis. We also study non-canonical sites, those outside of the native hormone, or orthosteric, binding sites. We have identified several GPCR ligands that allosterically modulate orthosteric ligand binding and target sites that are often located in regions that display higher sequence variability among receptor subtypes. Again, our intention is to target specific receptor subtypes. The structural work on the GPCR-G protein complexes have also revealed some unprecedented conformational changes in G protein structure. Some of these changes are associated with G protein activation while the functional consequences of other structural changes remain elusive. More recently we have have been heavily engaged in studies to address the functional role of these dramatic conformational changes and the relationship to disease. Some of these studies resolved a major question regarding the signaling differences in G protein splice forms, specifically the short and long forms of the stimulatory G protein, Galpha-s(s) and Galpha-s(l), respectively. We demonstrated that Galpha-s(l), but not Galpha-s(s), regulates extracellularly regulated kinases (ERK), and that this long isoform is tied to a devastating blood disorder, myelodysplastic syndrome (MDS). We speculate that these aberrations in Galpha-s(l), specifically, may be involved in other pathologies such as cancer. The Sunahara lab has also been developing protein-based therapeutics using structure-guided design and validation. A notable therapeutic is an enzyme that hydrolyzes cocaine. Through structural and computational approaches the Sunahara lab and collaborators developed a thermostable form of the enzyme that has recently progressed through Phase II clinical trials as an antidote for cocaine overdose. The laboratory continues to engineer the enzyme to optimize its potential as a treatment for cocaine abuse, a debilitating disease that would require long-term and sustained therapeutic actions. Dr. Roger Sunahara on the web UCSD Profile Google Scholar ResearchGate LinkedIn Dr. GPCR Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Home → Flash News → ep 169 with sokhom pin some 3 Published on July 15, 2025 Category Dr. GPCR Podcast Stayed when others pivoted. Now leading the field. While others left GPCRs behind, Sokhom S. Pin stayed the course. From DuPont to Cerevel, he focused on GPCR biology and became one of the few deep experts still standing when the field surged back. Patience. Passion. Positioning. 🎧 Hear about the journey: https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-169-with-dr-sokhom-pin #GPCRdrugdiscovery #GPCR #GPCRtrainingprogram #DrGPCR Previous Next Recent Articles

<< Back to podcast list Strategic Partner(s) Dr. Khaled Abdelrahman, Victoria Rasmussen and Madelyn Moore About Dr. Khaled Abdelrahman " Dr. Khaled Abdelrahman graduated in 2006 with a BSc in Pharmaceutical Sciences from Alexandria University (Egypt) followed by MSc in Pharmacology in the same university that was conferred in 2009. He joined the laboratory of Dr. William Cole at the University of Calgary in 2010 for his Ph.D. where he studied the molecular basis underlying altered cerebrovascular function and blood flow in type 2 diabetes. In 2015, He joined Dr. Stephen Ferguson’s laboratory in the Departments of Cellular & Molecular Medicine and Neuroscience at the University of Ottawa as a Postdoctoral Fellow to explore novel G protein-coupled receptor (GPCR) candidates that can be targeted pharmacologically to slow neurodegeneration. He has been also studying what aspects of GPCR signaling are regulated in a sex-selective manner and how this can influence drug discovery in the area of neurodegenerative diseases. He is also a Registered Pharmacist in Canada and held two of the most prestigious Clinician Postdoctoral Fellowships offered by Alberta Innovates and Canadian Institutes of Health Research. He received the Canadian Society of Pharmacology and Therapeutics Postdoctoral and Publication awards along with many Young Scientist Awards from the American Society for Pharmacology and Experimental Therapeutics. " Dr. Khaled Abdelrahman on the web Twitter PubMed Google Scholar Dr. GPCR About Victoria Rasmussen "Victoria Rasmussen is a graduate fellow in Dr. Thomas Sakmar’s laboratory at The Rockefeller University, where she study’s the signaling and degradation of G protein-coupled receptors. She completed her undergraduate education at Providence College, receiving a B.S. in Biology and a B.A. in psychology. During her time at Providence College, she received the Walsh Grant Fellowship to develop novel methods of synthesizing 2 -imidazoline scaffolds to be used as proteasome modulators in the laboratory of Travis Bethel. Victoria started her Ph.D. at the Tri-Institutional Ph.D. program in Chemical Biology, where she joined the lab of Thomas Sakmar at The Rockefeller University. She is currently working to understand the signaling and degradation of GPCRs in disease states to help test the feasibility of using protein-targeted degradation as a therapeutic strategy. " Victoria Rasmussen on the web Tri-Institutional PhD Program in Chemical Biology Rockefeller University LinkedIn Dr. GPCR About Madelyn Moore "Madelyn (Maddi) earned her B.S. in Biochemistry from the University of Minnesota-Duluth in 2020. In her time as an undergraduate, Maddi was a researcher in Dr. Amanda Klein's lab where she helped to investigate the role of various ATP-sensitive potassium channels in pain and opioid tolerance. From there, she went on to be a research technologist in Dr. Richard Vile's lab at Mayo Clinic where she aided the evaluation of tumor-specific oncolytic viruses. Maddi is currently a second year Ph.D. student in the Molecular Pharmacology and Therapeutics (MPaT) Graduate Program at the University of Minnesota. Advised by Dr. Lauren Slosky, she is working to understand the mechanism by which a new class of biased allosteric modulators for the neurotensin receptor 1 (NTSR1) act to attenuate the behavioral effects of methamphetamine." Madelyn Moore on the web MPaT PubMed LinkedIn Dr. GPCR Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Discover how finance and science intersect in this Dr. GPCR Podcast episode with Joe St. Germain and Chuck DeWeese, as they share what it takes to build mission-driven startups and research organizations. << Back to podcast list Strategic Partner(s) Finance is Science too: How Numbers Keep the Lights On with Chuck DeWeese & Joe St. Germain In Episode 165 of the Dr. GPCR Podcast, host Dr. Yamina Berchiche welcomes Chuck DeWeese and Joe St. Germain of Company Launch Partners for an inspiring discussion on the intersection of accounting, entrepreneurship, and nonprofit mission building . With the Dr. GPCR ecosystem officially becoming a nonprofit, this episode offers valuable insight into the financial backbone required to scale scientific and community-driven initiatives. 1. The Launch Pad: Company Launch Partners Joe St. Germain, founder of Company Launch Partners, shares how he transitioned from corporate finance to creating a service firm dedicated to startups and nonprofits . A self-declared problem-solver, Joe describes how working with early-stage companies reignited his passion for helping others build impactful ventures. Chuck DeWeese, controller at CLP, joined the mission after pivoting from a sales career into accounting, where he found his professional calling in " making the numbers make sense ." "There’s something really sick with accounting people... that accounting high when everything reconciles." – Chuck DeWeese 2. The Nonprofit Spark: Partnering with Dr. GPCR The episode dives into how Joe and Chuck began collaborating with the Dr. GPCR ecosystem. Yamina reached out to Joe with accounting questions during his vacation—an email that sparked a partnership. Chuck stepped in to help structure the nonprofit’s financial framework , showcasing how specialized knowledge and timing can catalyze long-term collaborations. “You always email me when I’m on vacation.” – Joe St. Germain (laughing) 3. Accounting Highs & Scientific Parallels Yamina draws a parallel between reconciling complex financial data and a scientist getting a long-awaited result. Both Chuck and Joe agree: accounting is like solving puzzles. It's about structure, order, and breakthrough moments , not unlike the life of a researcher. “Finance grows the beans, but you don’t get to that point until you count them.” – Chuck DeWeese 4. Jumping Off the Cliff: The Entrepreneur’s Leap Joe shares the risks of launching a business while supporting a family, emphasizing the mental resilience and self-care needed. He compares entrepreneurship to a scientist’s journey: uncertainty, trial-and-error, and the necessity of mentorship. "I’m a startup working with startups. That support system made the leap manageable." – Joe St. Germain 5. Networking: Relationship Over Transaction Both guests stress that business is built on relationships , not transactions. Joe often helps people with problems unrelated to accounting, simply to build trust. Chuck adds that networking is about planting seeds and being patient. “We assess and sometimes say: ‘You’re not quite at our level yet. Let’s help you set up and come back when you’re ready.’” – Chuck DeWeese 6. Accounting for Grants: Buckets, Structure & Strategy The discussion covers the unique complexities of grant accounting in nonprofits. Unlike startups, nonprofits must adhere to strict allocation rules. Chuck explains that every dollar needs a bucket and purpose. "Accounting counts the beans with 100% accuracy. Finance grows the beans, but you don’t get to finance without accounting first." – Chuck DeWeese 7. Culture Fit: Who Gets to Join the Team? When building their team, Joe and Chuck prioritize character over experience . They look for organized, upbeat, can-do individuals—many of whom are working mothers. A standout story is Kendra, a team member with no prior accounting experience who quickly became a key contributor. "Hire for character, train for skill. That’s how we grow." – Joe St. Germain 8. The Joy of Building with Purpose Joe’s personal mission— to make a positive impact on people’s lives —drives their client selection. They avoid companies that don’t align with their values, like the vaping industry. Instead, they seek out startups and nonprofits working toward social impact and innovation . “We’ve only turned down one client for ethical reasons. We want to make the world better.” – Joe St. Germain 9. The Science of Finance: A Shared Language Throughout the episode, Yamina and her guests underscore that finance and science share more than most people think —both require rigor, discipline, and a process-oriented mindset. This realization forms a deep connection between accountants and scientists alike. “Accounting is a science too. You build systems, track data, and interpret outcomes.” – Chuck DeWeese 10. Final Reflections: Growing Together Yamina closes with the story behind the podcast’s creation—how a moment at a Starbucks in Target led her to launch a platform that now empowers GPCR scientists worldwide. It’s about finding the right people, solving hard problems, and creating something bigger than yourself . "I come alive when I do this. The podcast is about connecting people through science and story." – Yamina Berchiche Summary made with AI ________ Key Takeaway Whether you're launching a startup, building a nonprofit, or running a research lab, success comes down to relationships, integrity, and learning the systems that power sustainability . And yes, finance is a science too. Keyword Cloud: GPCR research community , Dr. GPCR ecosystem , GPCR training program , GPCR online course , GPCR podcast , GPCR data platform , G protein-coupled receptors , GPCR scientist network , GPCR drug discovery , GPCR webinar series Summary created by AI About Company Launch Partners Company Launch Partners is a fractional finance and accounting service focused on early stage companies. Simply put, we partner with companies to help them launch. The company has been working with startup companies since 2017, serves 25 clients and has assisted over a 100 companies as they start their journey. Company Launch Partners on the web Company Launch Partners Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Home → Flash News → New Episode Alert! 🎙️ Ep. 163 of the Dr. GPCR Podcast is here! 🚀 This time, we sit down with Dr. Dmitry Veprintsev to discuss the importance of asking the right GPCR questions. Whether you're a researcher, student, or GPCR enthusiast, this episode is packed with insights that will challenge how you think about your experiments. ✳️Tune in at https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-163-with-dr.-dmitry- #DrGPCR #GPCRPodcast #Pharmacology #DrugDiscovery #Biotech #GPCRs Published on April 1, 2025 Category Dr. GPCR Podcast New Episode Alert! 🎙️ Ep. 163 of the Dr. GPCR Podcast is here! 🚀 This time, we sit down with Dr. Dmitry Veprintsev to discuss the importance of asking the right GPCR questions. Whether you're a researcher, student, or GPCR enthusiast, this episode is packed with insights that will challenge how you think about your experiments. ✳️Tune in at https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-163-with-dr.-dmitry- #DrGPCR #GPCRPodcast #Pharmacology #DrugDiscovery #Biotech #GPCRs Previous Next Recent Articles

Submit your partnership request with our easy-to-use online form. Join Dr. GPCR Ecosystem and collaborate with us to make a positive impact. Strategic Partners Back to Partners List Submit Thanks for submitting! We'll get back to you to set up a meeting.

Expert support, trusted CROs, and ready-to-use tools to accelerate GPCR drug discovery, reduce risk, and advance your discovery-stage projects. Dr. GPCR Foundry: Accelerate GPCR Drug Discovery Move from idea to insight—faster, smarter, and with confidence. Partner with our nonprofit team for expert guidance, trusted CRO collaborations, and field-tested tools that de-risk your GPCR programs and keep momentum strong. 👉 Book a Free 30-min Strategy Call What Is the Dr. GPCR Foundry? In short: The Foundry gives you the right people, tools, and insight to move your GPCR programs forward — faster and with confidence. What Is the Dr. GPCR Foundry? The Dr. GPCR Foundry is a nonprofit platform designed to help biotech leaders accelerate GPCR drug discovery with precision, credibility, and speed. Here’s how we add value: Bridge early discovery to development: transform receptor concepts into validated, investment-ready programs. Leverage a trusted GPCR partner network: access curated CROs, consultants, and collaborators with proven track records. De-risk decisions: gain expert strategic guidance on study design, timelines, and partner selection before execution. Scale internal expertise: upskill teams through specialized GPCR programs and leadership-level insights. Partner through purpose: as a nonprofit, we align with your mission—accelerating breakthroughs, not billing hours. Why Biotechs choose Dr. GPCR Foundry? The Foundry is built for GPCR biotech companies at the discovery stage . 🔬 Validate your first target with confidence ⏱️ Scale programs faster with proven timelines 🤝 Access credible GPCR CROs and expert consultants 📚 Train and upskill your team with specialized programs 📢 Gain visibility through trusted media partnerships We connect you to: Specialized Consultants & KOLs Trusted GPCR CROs Learning Resources Media Visibility Opportunities Who is the Foundry for? The Dr. GPCR Foundry supports biotech teams working on discovery-stage GPCR programs who need expert guidance, trusted partners, or a clearer path forward. Wherever you are in your journey — from first target to scale-up — we’re here to help you move faster, smarter, and with confidence. You’ll benefit most if you’re: ✔ A GPCR biotech startup validating your first target ✔ An established biotech ready to expand or optimize discovery programs ✔ Looking for credible GPCR CROs and consultants to advance your work Explore Resources Expert Guidance — Built for GPCR Biotechs Get strategic clarity on your next discovery move — from target validation to translational strategy. Avoid costly missteps with data-driven, expert-backed recommendations. Gain confidence and direction with a customized roadmap aligned to your biotech’s goals and timeline → Book Your Free Strategy Call Specialized Training — Build GPCR Expertise Within Your Team Strengthen your team’s GPCR knowledge with structured, science-driven training . Learn proven experimental and analytical methods that accelerate discovery outcomes. Stay ahead of the curve with expert-led programs designed for real-world biotech challenges. → Explore the Dr. GPCR University GPCR Insights in Action Transform complex pharmacology into clear, practical understanding that drives discovery. Learn how to apply GPCR concepts and data to real-world research and development. Build confidence through expert-led lessons, case studies, and proven experimental strategies. → Explore Terry's Corner Visibility & Reputation — Amplify Your Scientific Voice Showcase your expertise and achievements within a trusted global GPCR network. Build credibility and visibility among scientists, biotechs, and CRO partners worldwide. Strengthen your organization’s presence through authentic storytelling and mission-aligned collaborations. → Email Hello@DrGPCR.org to learn more or Book a call below Team Advantage — Grow Together, Discover Faster Unite your scientists under one trusted GPCR learning hub. Give every team member access to the same expert-led, science-driven resources. Build collective expertise and alignment that accelerates discovery outcomes. → Explore Dr. GPCR University Team Membership Biotech Growth Workshops — Scale With Strategy Replace trial-and-error with structured frameworks tailored for biotech growth. Learn to scale confidently through data-driven, real-world case studies. Gain clarity and direction to move your biotech forward—faster and smarter. → Explore Timeline Strategy Help Your GPCR Discovery Program Succeed Work with the Dr. GPCR Foundry to accelerate your discovery programs with clarity, confidence, and trusted partnerships. Our core support areas: Discovery Consulting & Strategy Expert guidance to de-risk projects, refine strategy, and drive scientific progress. Visibility for GPCR Solution Providers Strategic media partnerships that connect your company with biotech innovators and showcase your expertise Training & Upskilling Specialized, insight-packed courses designed for discovery-phase GPCR teams. Tools & Templates Ready-to-use frameworks and resources tailored to the realities of discovery-stage GPCR work ✉ Contact Us Our Partners Join these innovative organizations already benefiting from the DrGPCR Foundry. Book Plan Your Next Move in GPCR Discovery Meet directly with Dr. Yamina Berchiche for a focused strategy conversation to align your goals, uncover opportunities, and map your next steps. Let's move your GPCR discovery program forward. Wherever you are in your discovery journey, the Foundry helps GPCR biotech companies move faster and reduce risk. Let's discuss your next step.

Meet the sponsors who make the Adhesion GPCR Workshop 2024 possible, supporting global collaboration and innovation in GPCR research. Home Registration Full Agenda Venue Travel Tips Sponsors Special Issue on Adhesion GPCRs OUR SPONSORS Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Sponsor Us Platinum Sponsors Bronze Sponsors Collaborating partners Contact us for sponsorship Register for the Adhesion GPCR 2024 Learn more about the Adhesion GPCR workshop 2024 Up About the event Learn more about the Adhesion GPCR workshop 2024 and its preliminary program. Up About the venue Discover Cinvestav, the host venue for the upcoming workshop. Up Abstract Submission Submit your research abstracts following our guidelines to present at the conference. Up Traveling Tips Find essential tips about Mexico City, including transportation options and local insights.

Home → Flash News → Terry's Corner is Officially LIVE! 🎉 This is your new go-to for mastering drug discovery pharmacology. No fluff, just clear, on-demand insights from Terry Kenakin. Building core expertise? Master dose-response, binding, kinetics, and foundational models. Driving drug discovery? Apply pharmacology to selectivity, ADME, and strategic decision-making. An experienced drug hunter? Sharpen your edge with allosteric bias, residence time, and translational PK/PD. Learn on-demand, apply immediately: https://terrykenakin.com #DrGPCR #GPCR #pharmacology #TerrysCorner #DrugDiscovery Published on July 2, 2025 Category Terry's Corner Terry's Corner is Officially LIVE! 🎉 This is your new go-to for mastering drug discovery pharmacology. No fluff, just clear, on-demand insights from Terry Kenakin. Building core expertise? Master dose-response, binding, kinetics, and foundational models. Driving drug discovery? Apply pharmacology to selectivity, ADME, and strategic decision-making. An experienced drug hunter? Sharpen your edge with allosteric bias, residence time, and translational PK/PD. Learn on-demand, apply immediately: https://terrykenakin.com #DrGPCR #GPCR #pharmacology #TerrysCorner #DrugDiscovery Previous Next Recent Articles

Join Dr. GPCR and become an Ecosystem Contributor! Discover how you can make a positive impact on the field and inspire others to do the same. Ecosystem Contributor - Coming Soon -

Discover the mission, vision, and people behind the Dr. GPCR Ecosystem: uniting scientists, biotech, and innovators to advance GPCR research worldwide. Who We Are We are a global network of scientists, biotech innovators, pharma professionals, CRO leaders, and vendors—united by one mission: to make working on GPCRs easier, faster, and more collaborative. Dr. GPCR is both expert-led and community-first. We’re building together, with input from across the field. About Dr. GPCR Ecosystem We unite the GPCR Community to advance drug discovery Where GPCR Experts Move Science Forward Join the global community accelerating GPCR drug discovery through trusted insights, expert tools, and powerful connections. Join Free & Get Our Weekly News See Why it Matters 6,600+ followers 200+ Research Labs 1,500+ Scientists 50+ Biotech Companies Built by Scientists. Driven by Impact. Dr. GPCR began as a podcast. Now, it's a global ecosystem of scientists, biotech teams, CRO leaders, and trainees working to move GPCR science forward—together. We created this space to make trusted knowledge and collaborations easier to access—without noise, fluff, or hype. What We Believe The Ecosystem was built with five key beliefs: Scientific rigor first This is a space for data-driven work, not hype. Usefulness over flash Every piece of content and feature must be practical. Transparency builds trust We're open about who we are and what we do. Collaboration is key Progress in GPCR science requires a collective effort. Inclusion matters We welcome diverse voices, experiences, and expertise. We designed the Ecosystem to support your work —no matter where you are in your GPCR journey. Our Journey (So Far) From the first podcast episode to a global platform, it's all built by and for the GPCR community. 2020 First Podcast Episode Launched our podcast to share expert insights with the scientific community. 2021 2nd Annual Summit Increased our reach and impact with the GPCR Community 2022 Community Platform Expanded beyond content to create a dedicated space for GPCR scientists to connect. 2023 First Symposium Inaugural Dr. GPCR Symposium with over 100 attendees 2024 GPCR University Launched comprehensive courses and expert talks to deepen scientific understanding. 2025 Terry's Corner & Consulting Launched our exclusive program with Dr. Kenakin and offered to CROs consulting services See Full Timeline The Field Is Growing—but Fragmented As GPCR scientists, we know the problem: too much noise, too little time, and nowhere to connect that's built for us. We built Dr. GPCR to: Curate relevant data—not overwhelm you with it Connect researchers with CROs, peers, and biotech leaders Provide high-quality tools and expert insights on demand Whether you're in a lab, launching a startup, or prepping for due diligence, we built this for you. The GPCR Challenge Scientists waste an average of 12 hours per week searching for relevant GPCR research and connections. Our ecosystem cuts that time by 80%. You'll Be in Good Company From PhDs to CRO execs to rising biotech founders—this is a vetted, mission-aligned community built to help you move faster. Premium Members Include: ✔ Drug hunters at early-stage biotechs ✔ CRO leaders building assays and tools ✔ Academic researchers moving into translational work ✔ Teams preparing for fundraising or due diligence Expert Contributors Include: ✔ Terry Kenakin, with his exclusive series on GPCR pharmacology ✔ Sam Hoare, simplifying GPCR data analysis ✔ Global CROs and biotech leaders, contributing behind-the-scenes tools and insight What Makes the Ecosystem Different Built for Drug Discovery Designed by scientists in the GPCR space to accelerate your research goals Collaborative by Design Connects researchers, CROs, and biotech teams—not just profiles, real relationships. Results-Driven Every tool and content block is built to help you make a decision or move forward. ✔ GPCR-specific content ✔ Expert curation ✔ Vetted community What Joining the Ecosystem Looks Like 1 Join Free Sign up in seconds. You'll instantly receive the GPCR Weekly News (free version). 2 Get Verified We manually review each profile to ensure trust and scientific relevance. 3 Start Exploring Browse free content, community updates, and learn what's available. 4 Upgrade Anytime Premium unlocks exclusive courses, community features, and deeper insights. Start Your Journey Today Meet the Leadership Founder & Director Yamina Berchiche Get in Touch Board Member Anne M. Quinn Get in Touch Board Member Maria Waldhoer Get in Touch Co-Founder Attila Foris Get in Touch Board Member JoAnn Trejo Get in Touch Chief Matchmaker Mark Schmeizl Get in Touch Why Upgrade to Premium Everyone who joins receives the free Weekly News. Premium gives you everything else—the full toolbox for moving science forward. Free Membership Includes: ✔ Free version of GPCR Weekly News - straight to your inbox! ✔ Select news and content ✔ Ecosystem and podcast updates Premium Members Unlock: ✔ Full Weekly News access – All GPCR papers, events, jobs + expert commentary ✔ Dr. GPCR University – 5 on-demand GPCR courses, 1 project management course, 200+ expert talks ✔ Community tools – Member directories, messaging, and forums Partners Who Drive our Mission Partner Benefits Visibility to GPCR experts Direct connections Industry insights Explore Partnership Opportunities Ready to Join the Movement? Start free. Upgrade when you're ready. Dr. GPCR helps you stay ahead of the curve in science and strategy. Unlock Premium Access Join Free Now

Join the Dr. GPCR Affiliate Program and earn commissions by helping connect the global GPCR community. Share our ecosystem, courses, and events to advance drug discovery together. Dr. GPCR Affiliate Program Earn by Empowering the GPCR Ecosystem Help us connect scientists, founders, and innovators while earning commissions for every member, partner, or course you bring into the Dr. GPCR community. Become our Brand Ambassador Our vision is to build the best platform for the GPCR community and help you the scientists and business owners to share their experiences with others, get help, and find the perfect tools, colleagues, build their strategy and advance our field. As an ambassador, with the Affiliate Program, you'll earn a commission whenever your referral link is used and a qualified purchase has been made by your friends, colleagues, or followers who are also part of the GPCR field. Become our Brand Ambassador About Dr. GPCR Ecosystem We aspire to provide opportunities to connect, grow, and thrive together as a dynamic group. The goal is to better understand and exploit the druggability of GPCRs, together. The Dr. GPCR Ecosystem members have the opportunity to solve problems, find answers to their questions, identify the perfect service provider, and, most importantly, boost their GPCR project with just a few clicks. The Ecosystem is designed for all GPCR professionals to have an affordable and highly effective way to showcase their knowledge, connect, and advance the field, together. About the Dr. GPCR brand ambassador affiliate program Who can be a Dr. GPCR ambassador? Scientists and trainees with a strong GPCR background who like and want to create content by writing articles about their favorite GPCR topics and sharing these on social media platforms such as LinkedIn and other options listed at the end of this page. Who is eligible for the Dr. GPCR affiliate program? A GPCR background is mandatory independent of your current position and industry. You also must be an individual Dr. GPCR Ecosystem membership holder. For full details on eligibility, please read our Affiliate Policy . How do I apply for the affiliate program? To become an affiliate, you must create an account here . How does the Dr. GPCR affiliate program work? After becoming a member of the affiliate program, you'll get your personalized link where you can send your potential clients. After every qualified sale, you will earn a commission of $50. How does the commission work? Each qualifying sale earns a commission (excluding sale cancellations). Does it cost me anything to become an affiliate? The program is free to join; there are no monthly charges and no minimum sales requirements. However, the number of ambassador members is limited. Dr. GPCR reserves the right to remove the least active members from the program. Can I invite someone to participate? Yes! You can invite anyone to participate, and we welcome anyone if they are qualified. Do I need to sign a contract? There's no contract to sign when joining our program. You will be required to agree to our Terms and Conditions and our Affiliates Policy when you sign up on Ecosystem.DrGPCR.com. You can leave the program at any time by contacting us. Dr. GPCR may also remove affiliates from the program at any time. Is there an exclusivity agreement when joining? There's no exclusivity agreement. You can take part in other affiliate programs as well as be part of ours. Are affiliates outside of the U.S. eligible for the Affiliate Program? Yes, you may join the affiliate program as long as you have a verified PayPal account. What type of channels, tools, and techniques can I use to promote Dr. GPCR Ecosystem? OK to use: - Writing, blogging, guest blogging, - Podcast, video, vlog - Social media sharing, - YouTube & TikTok channels, - Business Page and website, - Informational and fan sharing, - Presentations and meetups. Not OK to use: Advertising Spam Anything misleading or annoying Social media bios Paying or offering intensives for the use of your link How do I track my earning? We use a third-party provider, GoAffPro.com , where you'll create your own account and through your dashboard, you can track all your activities. When will I receive my affiliate commissions? Affiliate payments are processed and sent directly to your PayPal in 7 to 30 days. We could hold payments up to 30 days to allow for processing, chargebacks, etc. Good Faith We introduce programs such as the Dr. GPCR Ambassador, in good faith and expect the same good faith in return. Please note that we may withhold awards where we believe customers are acting in bad faith or otherwise acting contrary to the intent of this program. To be clear, commercializing, advertising, publishing, mass distributing, selling, or paying for the use of referral links is not appropriate, and we will not honor such links. We cannot cover every nefarious scenario, nor will we attempt to, but we do promise to be fair and reasonable. Closure We are so excited about the Dr. GPCR Ambassador program. It will be a remarkable journey and fun to build together the "next-generation" platform for the B2B industry. With your help, we can create a world where the living experience is joyful and worry-free. Are you ready? Sign up , explore, and connect with us. Become our Brand Ambassador

Fast-track your biotech investments with VC Insights. Access expert guidance, vetted CROs, and data-driven strategies to invest smarter and move faster in GPCR drug discovery. Home About Services News Get in Touch Welcome VC Insights Fast Track Your Next Biotech Bet Get decision-grade data, vetted CROs, and expert guidance—so you move fast and invest smarter. I help you avoid costly delays, choose the right experiments, and unlock clear timelines that drive confident investment. Fast Track My Discovery The wrong CRO—or wrong experiments—can burn months and millions You're not here to fund academic detours. You're backing science that needs to move fast. But too often I hear: “We thought the experiments made sense—until the data didn’t help us decide.” “The CRO promised timelines they couldn’t hit.” “The team’s updates sound polished, but we can’t tell if they’re on track.” If you’ve said any of those, you’re not alone. That's where I come in : to pressure-test the science, align the strategy, and make sure every experiment earns its place. How I Drive Value Prioritize the Right Experiments Avoid noise. I help identify the experiments that truly matter—aligned to your milestones and inflection points. Translate project strategy into clear decision-driving assays Eliminate “nice to have” tests that stall timelines without payoff Match experiments to the specific phase and risk tolerance of the asset De-risk Your CRO Strategy I evaluate, select, and manage CROs that are fit-for-purpose—saving you time, cost, and rework. Audit and compare CRO options based on speed, quality, and fit Clarify deliverables and oversight to prevent rework and misfires Serve as a scientific bridge between VC, team, and CRO Move With Clarity and Speed Every week counts. I bring structure, decision frameworks, and momentum so your team stays on track. Build plans aligned to go/no-go moments, not busywork Drive regular check-ins that produce clear, actionable updates Anticipate delays and adapt quickly with contingency-ready paths " Yamina brings scientific clarity, leadership, and precision execution to complex pharmacological programs. I’ve worked with her on several discovery programs; in fragmented programs, she brought clarity and decision points that produced much better candidate progression. I am always delighted to work with Yamina as it always leads to an overall better and harmonious discovery program." - Terry Kenakin, PhD - UNC Chappel Hill ! Widget Didn’t Load Check your internet and refresh this page. If that doesn’t work, contact us. Let's turn complexity into confidence—with the data you need to move forward. Chat about My Discovery Send me a message First name* Last name Company name* Email* How Can I Help?* Send Message or Book My Call Menu Home Services About Ready to collaborate? Let’s talk about how I support GPCR discovery, pharmacology strategy, and cross-functional execution across biotech, VC, and CRO teams. Get in touch Connect LinkedIn Podcast Dr. GPCR Calendly ©2023-2025 All rights reserved by FindYooour, LLC & Dr. GPCR Corp Proudly created with Wix.com